Literature DB >> 27903669

Exertional dyspnoea in obesity.

Vipa Bernhardt1, Tony G Babb2.   

Abstract

The purpose of cardiopulmonary exercise testing (CPET) in the obese person, as in any cardiopulmonary exercise test, is to determine the patient's exercise tolerance, and to help identify and/or distinguish between the various physiological factors that could contribute to exercise intolerance. Unexplained dyspnoea on exertion is a common reason for CPET, but it is an extremely complex symptom to explain. Sometimes obesity is the simple answer by elimination of other possibilities. Thus, distinguishing among multiple clinical causes for exertional dyspnoea depends on the ability to eliminate possibilities while recognising response patterns that are unique to the obese patient. This includes the otherwise healthy obese patient, as well as the obese patient with potentially multiple cardiopulmonary limitations. Despite obvious limitations in lung function, metabolic disease and/or cardiovascular dysfunction, obesity may be the most likely reason for exertional dyspnoea. In this article, we will review the more common cardiopulmonary responses to exercise in the otherwise healthy obese adult with special emphasis on dyspnoea on exertion.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27903669     DOI: 10.1183/16000617.0081-2016

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  12 in total

1.  [Heart or lung? : Diagnostics and management of unclear exertional dyspnea].

Authors:  H Wilkens; M Held
Journal:  Herz       Date:  2018-09       Impact factor: 1.443

2.  Activity-related dyspnea in older adults participating in the Canadian Longitudinal Study on Aging.

Authors:  Chris P Verschoor; Sabit Cakmak; Anna O Lukina; Robert E Dales
Journal:  J Gen Intern Med       Date:  2022-07-11       Impact factor: 6.473

3.  Multidimensional aspects of dyspnea in obese patients referred for cardiopulmonary exercise testing.

Authors:  Bryce N Balmain; Kyle Weinstein; Vipa Bernhardt; Rubria Marines-Price; Andrew R Tomlinson; Tony G Babb
Journal:  Respir Physiol Neurobiol       Date:  2019-12-30       Impact factor: 1.931

4.  Dyspnea during exercise and voluntary hyperpnea in women with obesity.

Authors:  Matthew D Spencer; Bryce N Balmain; Vipa Bernhardt; Daniel P Wilhite; Tony G Babb
Journal:  Respir Physiol Neurobiol       Date:  2021-02-11       Impact factor: 1.931

5.  Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study.

Authors:  Sergio H R Ramalho; Mario Santos; Brian Claggett; Kunihiro Matsushita; Dalane W Kitzman; Laura Loehr; Scott D Solomon; Hicham Skali; Amil M Shah
Journal:  JAMA Netw Open       Date:  2019-06-05

6.  Transfer coefficient of the lung for carbon monoxide and the accessible alveolar volume: clinically useful if used wisely.

Authors:  J Alberto Neder; Mathieu Marillier; Anne-Catherine Bernard; Denis E O'Donnell
Journal:  Breathe (Sheff)       Date:  2019-03

Review 7.  The Importance of Respiratory Rate Monitoring: From Healthcare to Sport and Exercise.

Authors:  Andrea Nicolò; Carlo Massaroni; Emiliano Schena; Massimo Sacchetti
Journal:  Sensors (Basel)       Date:  2020-11-09       Impact factor: 3.576

8.  Exercise ventilation and dyspnea in the obese patient with chronic obstructive pulmonary disease: "how much" versus "how well".

Authors:  Jose Alberto Neder
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 2.444

9.  Sex differences in the ventilatory responses to exercise in mild to moderate obesity.

Authors:  Dharini M Bhammar; Bryce N Balmain; Tony G Babb; Vipa Bernhardt
Journal:  Exp Physiol       Date:  2022-07-17       Impact factor: 2.858

10.  Outcomes of Idiopathic Pulmonary Fibrosis Improve with Obesity: A Rural Appalachian Experience.

Authors:  Rahul G Sangani; Andrew J Ghio; Hasan Mujahid; Zalak Patel; Kristen Catherman; Sijin Wen; John E Parker
Journal:  South Med J       Date:  2021-07       Impact factor: 0.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.